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Abstract: Chagas disease (CD), caused by the intracellular protozoan Trypanosoma cruzi, is a parasitic illness endemic in 
Latin America. In the centennial after CD discovery by Carlos Chagas (1909), although it still represents an important 
public health problem in these affected areas, the existing chemotherapy, based on benznidazole and nifurtimox (both in-
troduced more than four decades ago), is far from being considered ideal due to substantial toxicity, variable effect on dif-
ferent parasite stocks and well-known poor activity on the chronic phase. CD is considered one of the major “neglected” 
diseases of the world, as commercial incentives are very limited to guarantee investments for developing and discovering 
novel drugs. In this context, our group has been pursuing, over the last years, the efficacy, selectivity, toxicity, cellular 
targets and mechanisms of action of new potential anti-T. cruzi candidates screened from an in-house compound library of 
different research groups in the area of medicinal chemistry. A brief review regarding these studies will be discussed, 
mainly related to the effect on T. cruzi of (i) diamidines and related compounds, (ii) natural naphthoquinone derivatives, 
and (iii) megazol derivatives.  
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1. INTRODUCTION 
  Chagas disease (CD) is a neglected illness caused by the 
protozoan Trypanosoma cruzi. Its life cycle involves haema- 
tophagous triatomine insects (vectors), diverse vertebrate 
mammalian hosts and different developmental forms of the 
parasite. Briefly, after the ingestion of bloodstream trypo-
mastigotes by the insect vectors from an infected mammalian 
host, there is the conversion to epimastigote forms, which 
proliferate and then differentiate into metacyclic forms 
within the posterior intestine of the triatomine. These infec-
tive parasite forms released within the faeces of the tria-
tomine can invade new vertebrate cells and undergo another 
round of differentiation into the intracellular amastigote 
forms, which proliferate and then transform back to trypo-
mastigotes, the form that disseminates the infection. CD still 
represents a serious health problem in Latin America, with 
an overall prevalence of about 12-16 million cases [1]. In 
humans, its acute phase is mainly oligosymptomatic involv-
ing sometimes flu-like symptoms; this phase is associated 
with low mortality levels (<8%), especially among children. 
In the chronic phase, although most patients remain asymp-
tomatic, after several months and even decades, about 30-
40% of them may develop clinical symptoms characteristic  
of this phase, mainly cardiac and or digestive alterations [2]. 
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This infection is the leading cause of infectious cardiac dis-
ease in endemic areas [3]. The transmission of CD occurs 
primarily via the vector (90%), but may also occur through 
blood transfusion and congenital transmission, in addition to 
laboratory accidents [4], organ transplantation [5], and inges-
tion of contaminated food and beverages [6]. Recently, this 
disease has also been recognised as an opportunistic disease 
in HIV-infected individuals [7]. Furthermore, it is now being 
reported throughout the world due to growing international 
immigration [8].  
  Despite effective efforts focused on vectorial and blood 
transmission control, which have resulted in an important 
decrease in the number of new infected cases, many chal-
lenges still need to be faced: (i) its peculiar epidemiology, 
characterised by a variety of risk factors (many potential 
vectors and reservoirs, different forms of transmission and 
diverse parasite isolates present in domiciliary, peridomicil-
iary and sylvatic environments) and, importantly, (ii) the 
lack of prophylactic therapies and effective chemotherapeu-
tic schemes [9].  
  Nifurtimox (Nf) and benznidazole (Bz) are the available 
drugs for the treatment of chagasic patients; however, due to 
their well-known toxicity and limited effect towards differ-
ent parasite isolates and disease phases, new drugs are ur-
gently needed [10-13]. Nf is currently produced and used 
predominantly in Central America and thus not available in 
Brazil. One of the main drawbacks of this drug is the high 
incidence of side effects, observed in up to 40% of patients, 
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and severe anorexia in addition to adverse neurological ef-
fects, such as restlessness, paresthesias, twitching, insomnia 
and seizures [14]. Compared to Nf, Bz has the advantage of 
lower side-effect rates, which include hypersensitivity (der-
matitis, generalised oedema, ganglionic infarction and joint 
and muscle pains), bone marrow depletion and peripheral 
polyneuropathy [15]. Bz production by LAFEPE (Labo-
ratório Farmacêutico do Estado de Pernambuco, Recife, Bra-
zil) will also include a new paediatric formulation recently 
supported by DNDi (Drugs for Neglected Diseases initiative) 
efforts. Regarding efficacy, both Bz and Nf provide parasite 
eradication in the acute phase of infection, although they 
require long-term therapies (up to 60 days), but neither are 
active in the prevalent chronic stage of the disease [10,16]. 
From the knowledge regarding the efficacy vs. toxicity of 
both nitro-heterocyclic compounds, the current recommenda-
tions for their use in CD include the treatment of all acute 
cases (including transfusion and laboratory-acquired disease 
and reactivation of infection in transplanted and other immu-
nosuppressed patients) and recent chronic cases (including 
children up to 12 years of age) [14]. On the other hand, the 
contra-indications of Bz and Nf treatment include pregnancy, 
liver and kidney failure, neurological diseases unrelated to 
CD, and advanced CD with grade III or IV cardiopathy 
(OPS/OMS), as well as other pathologies that may be wors-
ened by the treatment [15]. 
  In fact, despite their undesirable side effects and the exis-
tence of parasite strains naturally resistant to both com-
pounds, the major limitation of Bz and Nf is their insuffi-
cient anti-parasitic activity in the chronic form of the disease 
because approximately  80% of the treated chronic patients 
are not parasitologically cured [12,16]. On the other hand, 
clinical evidence suggests that, although not cured, the pro-
tective role of Bz treatment of chronic chagasic patients may 
achieve a significant reduction in the occurrence of electro-
cardiogram (ECG) changes and a lower frequency of deterio-
ration of their clinical condition [17-24]. However, there is 
no consensus regarding the therapy of these chronic patients. 
As reported, the decision is left to the individual physician, 
as there is no definitive evidence arguing for or against such 
therapy, especially for those that already exhibit symptoms 
or signs of cardiopathy. In this sense, a project called Ben-
znidazole Evaluation for Interrupting Trypanosomiasis 
(BENEFIT) is currently in progress and represents an inter-
national, multicentre, double-blind, placebo-controlled trial 
performed in Argentina, Bolivia, Brazil and Colombia with 
about 1,600 chronic chagasic patients with heart disease. 
BENEFIT aims to evaluate whether Bz treatment is able to 
significantly reduce parasite burden and addresses the unan-
swered question of whether etiologic treatment is beneficial 
for patients already presenting clinical manifestations of 
Chagas heart disease. In addition, BENEFIT aims to further 
explore the safety and tolerability profile of Bz [14]. 
  Despite the fact that since 1912, many attempts have 
been made to treat the disease and some promising targets 
have been reported, from the time that Nf and Bz was intro-
duced (1960-1970), only allopurinol and a few antifungal 
agents, including ergosterol biosynthesis inhibitors such as 
itraconazole, fluconazole and ketoconazole, have moved to 
clinical trials [25,26]. This situation may reflect (a) low in-
vestments by pharmaceutical companies, (b) mistaken con-
cepts regarding the absence of parasitism during the chronic 
phase, and (c) the lack of standard procedures for drug 
screening. At present, a desired drug candidate for CD would 
include the following: (i) high activity against the parasite 
forms present in the mammalian hosts and against different 
T. cruzi stocks, (ii) efficacy against both acute and chronic 
infections, (iii) oral administration in few doses, (iv) low 
toxicity and improved safety (including children and women 
of reproductive age), (v) low cost and high stability for a 
long shelf life in tropical temperatures, and (vi) high levels 
of tissue accumulation and long term half lives [27].  
  Thus, as alternative drugs are desperately needed to treat 
CD, this article presents an overview of the biological activ-
ity, toxicity, selectivity and cellular targets of three classes of 
trypanocidal compounds - diamidines and related com-
pounds, natural naphthoquinone derivatives, and megazol 
derivatives - that have been studied at the Laboratório de 
Biologia Celular (Instituto Oswaldo Cruz, Fiocruz, Brazil).  
2. DIAMIDINES AND RELATED COMPOUNDS 
  Aromatic diamidines are DNA minor groove binders that 
have long been used in infectious disease chemotherapy 
[28,29]. Their major drawback is poor oral bioavailability 
and unfavourable side effects; thus, aiming to overcome 
these problems, new dicationic analogues and prodrugs have 
been synthesised from different medicinal chemistry groups 
and largely assayed in vitro as well as in vivo [30]. One of 
these examples is the prodrug of furamidine (DB75), named 
DB289, that has been in phase III clinical trials against hu-
man African trypanosomiasis. Unfortunately, despite initial 
indications of low toxicity in African, Asian, Caucasian and 
Hispanic populations, recent studies using extended dosages 
led to a withdrawal of DB289 from further human trials [13].  
  In recent years, our laboratory has been evaluating the 
biological effect of aromatic diamidines and analogues upon 
T. cruzi. We found that although DB75 and its N-phenyl 
substituted analogue DB569 (Fig. 1) display equivalent 
DNA-binding properties, the latter exhibited higher in vitro 
activity in the low micromolar range against different strains 
and stages of the parasite [31]. In T. cruzi-infected mice, 
DB569 led to reduction of the parasite cardiac load, down-
modulation of cardiac CD8
+ T cell levels, and reversion of 
the ECG alterations induced by the experimental acute infec-
tion [32]. The ECG protection provided by DB569 was also 
found during the chronic infection. The reversion to and fur-
ther maintenance of a normal ECG profile in the DB569-
treated mice may be associated with the reduced cardiac 
CD8
+ lymphocyte infiltration and decreased parasitism, 
which might be ultimately contributing to higher mouse sur-
vival rates as compared to infected and untreated animals 
[33]. Additionally, as a higher trypanocidal effect of DB569 
was also found during the incubation of T. cruzi-infected 
macrophage cultures as compared to the same treatment of 
cardiac cell cultures [31], it is possible that diamidines may 
also be acting directly on the immune cells. This subject is 
highly exciting because, besides controlling the parasite 
proliferation, these dicationic compounds may also regulate 
the inflammatory response and thus modulate the extent of 
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  Another study performed using both amastigote and try-
pomastigote forms showed the in vitro efficacy of the di-
arylthiophene diamidine DB1362 (Fig. 1) at micromolar 
doses that did not cause any toxicity to the host cell [34]. 
This diamidine showed good trypanocidal effect at 4°C in 
the presence of plasma constituents (mouse blood), exhibit-
ing similar IC50 values as those found at 37°C in the absence 
of blood, arguing for its possible application in prophylaxis 
of blood banks. In vivo assays performed by the administra-
tion of only 2 doses of DB1362 at 25 mg/kg (the first at the 
parasitaemia onset and the second at the peak) reduced the 
parasitaemia levels by 40% and resulted in 100% protection 
against mortality induced by the acute infection in this ex-
perimental model. As previously observed with DB569, 
DB1362 also largely reduced cardiac parasitism (similar 
levels as Bz run in parallel) in addition to protecting against 
electric cardiac alterations due to T. cruzi infection [34].  
  Recently, the biological and ultrastructural effects and 
subcellular localisation of another series of synthetic hetero-
cyclic dicationic compounds were studied in T. cruzi [35]. 
These diamidines were selected aiming to determine their 
efficacy on both bloodstream trypomastigotes and intracellu-
lar forms of the parasite. These compounds can be divided 
into three main groups: (i) curved molecules the size of 
DB75 or larger (DB1645, DB1651), (ii) a curved molecule 
smaller than DB75 ( DB1582) and (iii) linear molecules 
smaller than DB75 (DB1627, DB1646, DB1670). The data 
showed that all compounds exerted low toxicity to mammal-
ian cells (LC50 > 96 M). However, although the first two 
groups (DB1645, DB1651 and DB1582) showed good try-
panocidal activity, providing IC50 values in the range of 0.15 
to 13.3 M, the smaller linear molecules were not effective 
[35].  
  Arylimidamides (AIAs), also previously known as re-
versed amidines, have extraordinary activity against both 
trypanosomatids, such as T. cruzi [36,37], and Leishmania 
spp. [38-40]. In contrast to the original diamidines, in which 
the imino group is directly attached to an aryl ring, AIAs 
present the imino group attached to an “anilino” nitrogen 
[39]. AIAs, such as DB889, present very high activity (at 
sub-micromolar and nanomolar levels) against intracellular 
amastigotes and bloodstream forms of different stocks of the 
parasite and also show superior efficacy to diamidines as 
well as other closely related compounds [41]. It is possible 
that the higher efficacy of AIAs as compared to diamidines 
may be related to their physical properties because while 
amidines are highly basic molecules with pKa values near 
11, the pKa values of AIAs are near 7. Thus, at physiological 
pH, amidines are protonated, cationic molecules, whereas the 
arylimidamides are essentially neutral. This difference may 
significantly affect not only absorption, but also distribution, 
and likely plays an important role in the differences in activ-
ity between AIAs and diamidines [35]. In another recent 
study, we reported the in vitro trypanocidal effects of several 
different heterocyclic cationic compounds, including dia-
midines, a monoamidine, an arylimidamide and a guanylhy-
drazone, and found that all compounds exerted, at low mi-
cromolar doses, a time-dependent trypanocidal effect to 
varying extents upon both intracellular parasites and blood-
stream trypomastigotes [37]. Among them, the higher po-
tency and selectivity of the AIA DB613A (Fig. 2), especially 
towards intracellular parasites (reaching a selective index of 
>126), corroborate the highly promising activity of AIAs 
against this parasite, which further justifies studies in ex-
perimental models of T. cruzi infection. Additionally, AIAs 
such as DB702 and DB889 (Fig. 2) also present very high 
trypanocidal activity against bloodstream forms incubated at 
4°C in the presence of blood sources (100% mouse blood), 
also showing the possible application of AIAs in the prophy-
laxis of blood banks [41].  
  Several potential transporters that effectively carry dia-
midines have been reported in some parasites, including Af-
rican trypanosomes, Leishmania spp. and Plasmodium falci-
parum  [42-44]. However, their uptake mechanisms in T. 
cruzi are still unknown and deserve investigation. On the 
other hand, the intrinsic fluorescence of most of these dica-
tionic aromatic compounds allows following their uptake 
and sub-cellular accumulation within the treated cells. Aro-
matic diamidines were localised in DNA-enriched organ-
elles, such as nuclei, and, more importantly, within the mito-
chondrial kDNA of T. cruzi [31,35,45]. In addition to the 
usual localisation of these compounds in the parasite nuclei 
and kDNA (with greater intensity in the latter structure), 
some diamidines, such as DB1582 and DB1651 (Fig. 3 ), 
were also found within punctate non-DNA-containing cyto-
plasmic organelles, possibly acidocalcisomes, although other 
non-DNA-containing organelles cannot be excluded [35]. It 
is possible that, as suggested for the African trypanosomes 
[46], the localisation of these compounds within these acidic 
organelles could play a role in their mechanism of action 
and/or act as storage sites in T. cruzi, and additional studies 
are necessary to clear up this matter. An important point to 
be considered is the unusual disorganisation of microtubules, 
with the occurrence of multiple axoneme structures observed 
in diamidine- and AIA-treated bloodstream trypomastigotes 
[35,41]. Up to now, no major alterations have been reported 
 
Fig. (1). Chemical structures of the aromatic diamidines DB75, 
DB569 and DB1362.  
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in both sub-pellicular and flagellar microtubules of T. cruzi 
after incubation with different classes of drugs that target 
microtubules, such as taxol, colchicine and vinblastine, pos-
sibly due to the high content of acetylated tubulin and/or 
poly-glutamylation of tubulin found in these parasites 
[47,48]. Because these structures in trypanosomatids are 
highly resistant to microtubule disrupters as compared to 
those in mammalian cells, they represent interesting targets 
for drug development and deserve further investigations re-
garding the alterations induced by these dicationic aromatic 
compounds.  
  In fact, although the exact mechanism of action of these 
heterocyclic dications upon T. cruzi as well as upon other 
trypanosomatids has not been clearly demonstrated, it is 
likely that multiple modes of action may be operative and 
that compound uptake represents a fundamental step in their 
action and contributing, in part, to their selectivity (Wilson et 
al. 2008; de Koning, 2001). On the other hand, several data 
suggest that at least part of the activity is related to their se-
lective binding to AT-rich sequences of kDNA minicircles, 
leading to the destruction of the kinetoplast and parasite 
death [29,49]. In fact, transmission electron microscopy 
studies showed that the structure of parasite mitochondria 
(and kinetoplasts) is highly altered by aromatic diamidines 
and by some AIAs at doses that do not affect mammalian 
host cells [31,35,41,45]. Flow cytometry studies confirmed 
that diamidines and AIAs target the mitochondria-kinetoplast 
complex of T. cruzi through the interference of these com-
pounds with the proton electrochemical potential gradient of 
the mitochondrial membrane of the parasite [34,41] and that 
diamidines, such as DB569 and DB75, trigger apoptosis-like 
death in bloodstream forms of T. cruzi [32]. However, the in 
vitro screening of 11 dicationic aromatic molecules against 
T. cruzi showed that, in agreement with previous data re-
ported in T. brucei [50], although all were localised to a 
higher extent within the kinetoplast than in the nucleus, no 
correlation could be found between compound activity and 
higher kDNA accumulation [45]. Additionally, it has been 
proposed that although diamidines are excellent minor 
groove DNA binders, this interaction itself could not fully 
explain their biological activity. Recent reports suggest that 
their association with DNA could represent an initial step, 
followed by topological changes leading to molecule insta-
bility and destruction and/or modification of DNA-protein 
interactions, leading to replication errors, DNA degradation 
and parasite death [29,51]. Other targets that have also been 
proposed include inhibition of tyrosyl-DNA phosphodi-
esterase, topoisomerases, protein kinase A, proteases and 
polymerases [52-54]. 
  In summary, the efficacy of these DNA binders, espe-
cially AIAs, against T. cruzi stimulates further studies aim-
ing to help establish a valuable scheme of therapy for CD. 
3. NATURAL NAPHTHOQUINONE DERIVATIVES  
  Naphthoquinones are compounds present in different 
families of plants. Their molecular structures endow them 
with redox properties, and they are involved in different bio-
logical oxidative processes. The biological redox cycle of 
quinones can be initiated by one electron reduction leading 
to the formation of semiquinones, unstable intermediates that 
react rapidly with molecular oxygen, generating free radi-
cals. Another alternative mechanism is reduction by two 
electrons, mediated by DT-diaphorase, leading to the forma-
tion of hydroquinone. These compounds act as inhibitors of 
electron transport, uncouplers of oxidative phosphorylation, 
DNA intercalating agents, and producers of reactive oxygen 
radicals [55-57], being considered privileged structures in 
medicinal chemistry studies.  
  Lapachol is easily isolated from the heartwood of trees of 
the Bignoniaceae family, while both -lapachone and -
lapachone are present only in small amounts. Previous re-
ports showed that against T. cruzi epimastigotes, -
lapachone increases the generation of reactive oxygen spe-
 
Fig. (2). Chemical structures of the arylimidamides DB889, DB702 
and DB613A.  
 
Fig. (3). Chemical structures of the aromatic diamidines DB1582 
and DB1651. 
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cies through formation of the semiquinone radical, leading to 
lipid peroxidation and inhibition of nucleic acid and protein 
synthesis [58-62]. T. cruzi is known to be deficient in reac-
tive oxygen and nitrogen species detoxification, being espe-
cially sensitive to oxidative stress conditions [63], and its 
single mitochondrion, containing a branched electron trans-
port chain and a specialised region rich in DNA named kine-
toplast [52], is an extraordinary drug target [27]. The ultra-
structural injuries observed in -lapachone-treated epimas-
tigotes [64] together with the increase in the generation of 
hydrogen peroxide clearly demonstrates the mitochondrial 
susceptibility of T. cruzi to naphthoquinones. 
  These naphthoquinones were used as starting points for 
medicinal chemistry studies, and through their reaction with 
amino-containing reagents, 14 oxazoles, 30 imidazoles, and 
10 other related heterocyclic compounds were synthesised. 
The reaction of 1,2-naphthoquinones with aromatic alde- 
hydes led to naphthooxazoles and naphthoimidazoles, easily 
separated by column chromatography, and in several in- 
stances, the latter type of derivative was obtained as the main 
product and easily isolated by vacuum filtration and crystal- 
lisation in hexane/ethyl acetate. The comparison of their ac- 
tivity on bloodstream trypomastigotes revealed that struc- 
tural features that produced an increase in lipophilicity, such 
as a furan moiety, methoxyl group, or an aliphatic side chain, 
may have contributed to the increase in the anti-T. cruzi  
effect [65]. Among the 80 compounds screened against try-
pomastigote forms, the most active were three naphthoimi-
dazoles derived from -lapachone with the aromatic moieties 
phenyl (N1), 3-indolyl (N2) and p-methylphenyl (N3) (Fig. 
4) [66-69], pointing to the tendency of trypanocidal activity 
in compounds in which aromatic structures were introduced 
at the imidazole ring linked to a naphthopyranic structure, a 
promising route in the search of heterocycles with potential 
activity against T. cruzi. The naphthoimidazoles N1, N2 and 
N3 were also active against intracellular amastigotes and 
epimastigotes of T. cruzi and presented low toxicity to host 
cells [70]. In epimastigotes, the compounds blocked the cell 
cycle and metacyclogenesis, inhibited succinate cytochrome 
c reductase and induced damage to the mitochondrion, Golgi 
complex and reservosomes. In trypomastigotes, the com- 
pounds caused alterations in the kinetoplast and mitochon- 
drion in addition to inducing blebs in the plasma membrane 
and DNA fragmentation [71-73]. The mitochondrion, reser-
vosomes and DNA were identified as the main targets in         
T. cruzi. The compounds’ precise mode of action upon the 
parasite appears to be complex; however, we can exclude 
damage caused by oxidative stress because, unlike the origi- 
nal naphthoquinones, N1, N2 and N3 do not easily undergo 
redox reactions. It is important to note that several trypano- 
cidal agents, such as benznidazole, contain imidazole moie- 
ties [74-76], which is consistent with the idea that the   
trypanocidal activity is associated with the imidazole   
skeleton. 
  Taking into account that molecular hybridization is a 
powerful approach for the design of new compounds based 
on the recognition of the pharmacophoric sub-unities in the 
molecular structure, new quinone derivatives were prepared 
exploring the electrophilicity of 1,2-quinoidal carbonyls by 
reactions with different heteroatom nucleophilic centres. In 
this context, different classes of derivatives were obtained by 
the hybridisation of naphthoquinones with [1,2,3]-triazoles 
or arylamines and screening as anti-T. cruzi compounds. 
Compounds based on [1,2,3]-triazole comprise an important 
class of aromatic heterocycles with a wide range of biologi-
cal and pharmacological activities. Their reaction with nor--
lapachone by Huisgen cyclisation under copper catalysis led 
to derivatives that were shown to be more active against T. 
cruzi than the parent quinone, with IC50/1 day values in the 
range of 17 to 359 mM, with the apolar phenyl-substituted 
triazole 6 being the most active (Fig. 5) [77]. From the reac-
tion of nor-lapachol with aryl amines, substituted ortho-
naphthofuranquinones were created, and two compounds, the 
4-methoxy- (NF1) and the 3-nitrophenylamino (NF2) de-
rivatives, were more active than benznidazole, the standard 
drug [78]. From C-allyl lawsone, three naphthofuranqui-
nones (NF3, NF4 and NF5; Fig. 5) were also assayed, show-
ing activity against trypomastigote, intracellular amastigote 
and epimastigote forms in addition to presenting low toxicity 
to the host mammalian cells [79]. Although there are several 
reports on the biological activity of naphthopyranquinones, 
data on naphthofuranic analogues are scarce. Ortho-
naphthoquinones, such as -lapachone, have already been 
reported to present higher trypanocidal activity in compari-
son to their para isomers [66]. NF3, which is a para deriva-
tive, was more active than the ortho-quinones NF4 and NF5. 
The three compounds were active against intracellular amas-
tigotes, causing a strong decrease in the percent of infection, 
while damage to the host cells was observed only in concen-
trations 10-fold higher than the doses effective against the 
parasite. Ultrastructural analysis of treated epimastigotes and 
trypomastigotes indicated a potent effect of the compounds 
on the mitochondria, which were significantly swollen and 
possessed a washed-out matrix profile [80]. NF3, NF4 and 
NF5 also led to a collapse of the mitochondrial membrane 
potential and specifically decreased mitochondrial complex 
I-III activity in both epimastigotes and trypomastigotes, 
which paralleled the reduction in succinate-induced oxygen 
consumption. The interference with electron flow at the in-
ner mitochondrial membrane by reduced naphthoquinones 
suggests that reactive oxygen species generation could pro-
mote a functional impairment of the mitochondrion because 
 
Fig. (4). Chemical structures of naphthoimidazoles derived from -
lapachone.  N1 [4,5-dihydro-6,6-dimethyl-6H-2-(phenyl)-pyran[b-
4,3]naphth[1,2-d]imidazole];  N2 [4,5-dihydro-6,6-dimethyl-6H-2-
(3-indolyl)-pyran[b-4,3]naphth[1,2-d]imidazole]; and N3 [4,5-
dihydro-6,6-dimethyl-6H-2-(4-methylphenyl)-pyran[b-
4,3]naphth[1,2-d]-imidazole]. 
NH
N
O
N1 
NH
N
O
NH
N2 
NH
N
O
N3 26    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Soeiro and
 Castro 
this organelle is crucial in the trypanocidal effect of these 
naphthofuranquinones in T. cruzi [80].  
  Such hybrid molecules endowed the quinones with redox 
properties, representing an interesting starting point for a 
medicinal chemistry program directed toward the chemo-
therapy of CD. Their facile synthesis opens the possibility of 
large-scale production with high yields that can be assayed 
in experimental mouse models. 
4. MEGAZOL DERIVATIVES 
  The 5-nitroimidazole megazol was shown to be highly 
active in vitro and in vivo against T. cruzi, including strains 
resistant to benznidazole [81-84], and has become a core 
structure for the design of new leads for the treatment of CD. 
Megazol has been described as a trypanothione scavenger, 
the cofactor for trypanothione reductase [85,86]. Despite its 
noteworthy trypanocidal activity, megazol development was 
discontinued due to reports of mutagenic and genotoxic in 
vitro effects [87-89].
 In the late 90s, with its resurgence as a 
new potential drug for African trypanosomes [90,91] and 
trying to circumvent its toxic profile, megazol began to be 
explored as a template for the design of new trypanocidal 
drugs [92-94].  
 From  the  in vitro screening using trypomastigote forms, 
eight 1,3,4-thiadiazole-2-arylhydrazones out of thirty-four 
synthesised megazol derivatives were selected based on their 
potent trypanocidal activities [95,96]. These compounds 
were prepared exploring the hypothesis that the introduction 
of a radical scavenger arylhydrazone moiety in the hetero-
cyclic framework of megazol could modulate the production 
of toxic nitro anion radical species, avoiding potentially 
mutagenic properties [97,98]. Guanylhydrazones have been 
previously shown to display strong activity against T. cruzi 
[99]. It is also well known that some functionalised hydra-
zone-related derivatives [100-102] presented trypanocidal 
activity, which could be correlated with an action on essen-
tial enzymes of T. cruzi, such as cruzipain and trypanothione 
reductase, potential targets of new drugs for CD [27]. Such a 
strategy led us to identify a new potent trypanocide proto-
type S1 (Brazilizone A) (Fig. 6), which was two times more 
potent than megazol against the infective bloodstream form 
of the parasite and was selected for subsequent in vitro and 
in vivo studies. An additional 7 megazol derivatives also 
displayed interesting bioprofiles, with IC50s/24 h in the range 
of 11 to 63 M: the 4-OH (S2); the lipophilic para-bromo (4-
Br) (S3); the 4-NO2 ( S4); 3,5-dit-Bu,4-OH (S5); the 4-Cl 
(S6); the 4-OMe (S7); and the 2-OH (S8) (Fig. 6) [103]. S1, 
S2 and S3 led to several ultrastructural alterations in trypo-
mastigotes and were also active against intracellular amas-
tigotes at concentrations that induced no toxicity to the host 
cell. T. cruzi-infected mice were treated with each of these 
three derivatives, and while S1 did not interfere with the 
course of infection, S2 led to a significant decrease of parasi-
taemia and S3 decreased mortality. In this context, as ob-
served in the literature [104], there is not always a direct 
correlation between the in vitro effect on the clinically rele-
vant trypomastigote and amastigote forms of T. cruzi and the 
results of the treatment in experimental models.  
5. FINAL COMMENTS  
  For more than 15 years, our group has been investigating 
the biological activity, toxicity, selectivity and cellular tar-
gets of different classes of compounds upon T. cruzi, in col-
laboration with research groups focused in medicinal chem-
istry. An overview of in vitro and in vivo studies dealing 
with aromatic diamidines, naphthoquinones and megazol 
derivatives was presently discussed, aiming to contribute for 
the current knowledge and development of new arsenal can-
didates with anti-T. cruzi efficacy. In our investigation of the 
mechanism of action of trypanocidal compounds an impor-
tant tool is electron microscopy for the determination of cel-
lular targets in the parasite. We observed that aromatic dia-
midines and naphthoquinone derivatives interact with T. 
cruzi DNA, promoting a remarkable chromatin condensation 
and fragmentation [70,71] and in some cases, leading to nu-
clear envelope dilation [80], at doses that do not affect 
mammalian host cell viability. Another DNA-enriched com-
partment is the unique mitochondrion of trypanosomatids 
which is deficient in reactive oxygen species detoxification, 
and as so an attractive drug target. Treatment with aromatic 
diamidines and naphthoquinone derivatives induced a severe 
mitochondrial swelling with loss of functionality confirmed 
by flow cytometry, fluorescence microscopy and biochemi-
cal approaches [31,34-36,70,71,80]. It is important to keep in 
mind, however, that induced mitochondrial alterations may 
be due either to a primary effect directly on this organelle or 
secondary lesions caused by loss of cellular viability trig-
gered by another cell component or metabolic pathway. 
Aromatic diamidines and megazol derivatives were shown to 
be active in vitro and in vivo against T. cruzi [32-34,103], 
however, interestingly, there is not always a direct correla-
tion between the in vitro effect on trypomastigote and amas-
tigote forms and that of the treatment in experimental mod-
els.  
 
Fig. (5). Chemical structures of natural naphthoquinone derivatives: 
NF1 [3-(4-methoxyphenylamino)-2,3-dihydro-2,2-dimethylnaphtho  
[1,2-b]furan-4,5-dione]; NF2 [3-(3-nitrophenylamino)-2,3-dihydro-
2,2-dimethylnaphtho[1,2-b]furan-4,5-dione];  NF3 [2,3-dihydro-2-
iodomethylene-4,9-dioxonaphtho[2,3-b]furan];  NF4 [2,3-dihydro-
2-iodomethylene-4,5-dioxo-naphtho[1,2-b]furan]; and NF5 [2,3-
dihydro-2-methyl-4,5-dioxo-naphtho[1,2-b]furan]. 
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  In the last decades only few compounds moved to clini-
cal trials for CD possibly due to the low rates of investments 
alocated in this area and to the lack of standardized protocols 
for drug screening. The peculiar epidemiologic characteris-
tics of CD (including different hosts, geographic environ-
ments, transmission routes and cycles, developmental forms 
and strains) require a continuous and appropriate evaluation 
on the disease control tools and keep this neglected disease 
as a relevant challenge for the health ministry of many de-
veloping countries on the American continent. The use of 
etiologic treatment not only in the acute phase, but also in 
chronic patients is strengthened by the growing evidence that 
the low-grade, incessant myocarditis seen in the later stage 
of CD is related to parasite persistence, along with unbal-
anced immune responses in some individuals, leading to a 
sustained inflammatory response that underlies the character-
istic lesions of chronic CD. Thus, the current concept is that 
parasite elimination and/or its burden decrease may hinder 
the outcome of this parasitic disease [12,14]. In this context, 
as no safe and fully effective drug is available, a collabora-
tive interdisciplinary network for pre-clinical studies on drug 
discovery is combining parasitology and cellular biology 
expertise, medicinal chemistry, SAR patterns, physical 
chemical properties analysis and pharmacological studies 
associated with standard procedures and harmonised experi-
mental  in vitro and in vivo models. Promising targets for 
Chagas chemotherapy includes kDNA, sterol metabolism, 
and parasite specific enzymes such as cysteine proteinase 
[27]. The knowledge of the crystal structure and the specific-
ity of the major T. cruzi cysteine protease, cruzipain, has 
allowed the design of specific peptidyl as well as non pepti-
dyl inhibitors [10,11]. Among the extensive list of com-
pounds that have been screened against T. cruzi in the last 
three decades, ergosterol biosynthesis inhibitors represent 
the most advanced candidates for new anti-T. cruzi agents, 
and among them, some new triazole derivatives that are able 
to inhibit the parasite’s C14 sterol demethylase are the most 
promising. Two of them, posaconazole (Schering-Plough 
Research Institute) and ravuconazole (Eisai Company), are 
poised for clinical trials in the short term, although the cost 
of manufacture of these new compounds may represent an 
obstacle [12]. However, until an ideal novel drug for the 
specific treatment of CD is identified, the use of alternative 
therapies, such as the use of combined therapy using Bz and 
Nf associated with old drugs already available in the market 
for other pathologies, represent a promising approach [15]. 
In addition, it is relevant to state the necessity to provide an 
all-around care through adoption of a biopsychosocial 
model considering the patient therapy in the context of the 
biological, psychological and social factors [105]. As previ-
ously pointed out, “…the more leads/approaches that pro-
gress to investigational drug candidates, the better chance 
that new treatments for this often fatal infection will be 
available to patients in the near future” [11]. 
 
Fig. (6). Chemical structures of megazol derivatives: S1, 3,4-dihydroxybenzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-
2-yl]hydrazine); S2 (4-hydroxybenzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]hydrazine); S3 (4-bromobenzylidene 
[5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]hydrazine);  S4 (4-nitrobenzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-
1,3,4-thiadiazol-2-yl]hydrazine);  S5 (3,5-ditertbutyl-4-hydroxybenzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-
yl]hydrazine); S6 (4-chlorobenzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]hydrazine); S7 (3-hydroxy-4-methoxy- 
benzylidene [5-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]hydrazine); and S8 (2-hydroxybenzylidene [5-(1-methyl-5-nitro-
1H-imidazol-2-yl)-1,3,4-thiadiazol-2-yl]hydrazine).  
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